Tag Archives: Surveyor Capital

Olema Adds $54M to Start Human Tests of Breast Cancer Drug Candidate

Olema Oncology has raised $54 million to advance its lead drug candidate into human tests, having been working in stealth since 2007 to develop a daily pill to treat women with breast cancer whose disease is driven by the hormone estrogen. San Francisco-based Olema announced Wednesday that the Series B financing round will allow it to start […]

Posted in National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , | Comments Off on Olema Adds $54M to Start Human Tests of Breast Cancer Drug Candidate

VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years. Now Johnson, CEO of San Diego-based cancer drug developer VelosBio, has secured $137 million to accelerate the company’s goal of developing targeted therapies based on an antibody program developed by Kipps that homes in on tumors with a […]

Posted in National blog main, San Diego, San Diego blog main, San Diego top stories, San Francisco blog main, Seattle blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

Annexon Adds On $100M to Advance Antibodies to Treat Neurodegeneration

Annexon Biosciences, a biotech founded in late 2014 by former Elan Pharmaceuticals executives, has added $100 million to its coffers to move its two clinical-stage programs along and to continue advancing its preclinical pipeline. The South San Francisco-based company is developing drugs for patients with autoimmune and neurodegenerative disorders that are caused by an abnormal […]

Posted in National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , | Comments Off on Annexon Adds On $100M to Advance Antibodies to Treat Neurodegeneration

Novartis Leads $100M Round for Fibrosis-Focused Pliant Therapeutics

When Novartis signed on as a partner to Pliant Therapeutics last fall, it also agreed to eventually take an equity stake in the smaller biotech. The Swiss pharmaceutical giant made good on that commitment Tuesday, leading a $100 million investment. Besides Novartis, the Series C round of funding adds so-called crossover investors, firms that invest […]

Posted in Boston blog main, Boston top stories, National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Novartis Leads $100M Round for Fibrosis-Focused Pliant Therapeutics

Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug

Spruce Biosciences has raised $88 million to advance clinical testing of a drug for a rare inherited endocrine disorder that can lead to a potentially life-threatening hormonal imbalance. San Francisco-based Spruce aims to treat a form of congenital adrenal hyperplasia (CAH), an inherited condition that leads to a deficiency in enzymes needed to produce certain […]

Posted in Detroit blog main, Detroit top stories, National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug

With Ex-Medivation Exec Hung at Helm, Nuvation Nabs $275M for Cancer

Nuvation Bio peeked out from stealth mode Monday to reveal $275 million in financing and an executive team stacked with biotech veterans. The cancer drug developer, which has offices in New York and San Francisco, is led by founder, president, and CEO David Hung, the former chief executive who steered Medivation to a $14.3 billion […]

Posted in National blog main, National top stories, New York, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on With Ex-Medivation Exec Hung at Helm, Nuvation Nabs $275M for Cancer

Oncorus Adds $79.5M to Steer Cancer-Fighting Virus to Human Testing

Nearly four years ago, the FDA approved a therapy that uses a virus to infect tumor cells and break them down—the first such viral therapy for treating cancer. Oncorus CEO Ted Ashburn says there’s room to improve on these oncolytic viruses and their role in immunotherapy, and his biotech startup is getting ready to show […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Oncorus Adds $79.5M to Steer Cancer-Fighting Virus to Human Testing

Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs

The biotech IPO train is rolling on without slowing as we head into a holiday weekend. The latest to lay the groundwork to go public are Sutro Biopharma and Arvinas, which both want Wall Street’s help to back human trials of experimental cancer drugs. South San Francisco, CA-based Sutro set a preliminary $75 million target […]

Posted in National blog main, New York blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs

Avrobio Raises $60M for Fabry Disease Gene Therapy, Rest of Pipeline

Avrobio has had encouraging early results testing its experimental gene therapy to treat Fabry disease, an inherited enzyme deficiency that leads to a dangerous fatty buildup in the body. As the biotech startup gears up for more tests, it now has $60 million more in financing to support those studies and the rest of its […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Avrobio Raises $60M for Fabry Disease Gene Therapy, Rest of Pipeline